U.S. Point of Care Technology Market Size, Share & Forecast 2026–2032
Report Highlights
- ✓Country: United States
- ✓Market: Point of Care Technology Market
- ✓Market Size 2024: USD 17.8 billion
- ✓Market Size 2032: USD 30.6 billion
- ✓CAGR: 7.0%
- ✓Base Year: 2025
- ✓Forecast Period: 2026–2032
Analyst Recommendation — File CLIA waivers early: Device makers should submit 510(k) applications bundled with CLIA waiver requests by the third quarter of 2026, targeting the 2027 Medicare Physician Fee Schedule cycle. Early waiver status places assays in pharmacy and physician office channels where reimbursement remains most durable.
U.S. Point-of-Care Technology: Market Overview
The U.S. point-of-care technology market is the largest national point-of-care testing market globally, estimated at USD 17.8 billion in 2024 and representing close to 40% of worldwide spending. Its distinctiveness comes from regulatory architecture: every test performed outside a central laboratory must clear FDA device review and carry a CLIA certificate, creating a two-gate entry sequence that few other countries impose. Hospitals, physician offices, urgent care centers, and retail pharmacies all compete for the same assays, and each setting carries different certification and reimbursement obligations.
Unlike the global norm, where emerging markets drive unit volume through low-cost glucose and infectious disease strips, U.S. demand skews toward higher-value molecular and immunoassay platforms. Abbott's ID NOW, Cepheid's GeneXpert systems, and Roche's cobas liat illustrate this premium positioning. Hospital emergency departments, primary care practices, and retail clinics account for the bulk of procedures, while home-use glucose monitoring remains the largest category by unit volume.
Growth Drivers in U.S. Point-of-Care Technology
Demographic pressure is the first driver. Adults aged 65 and older number roughly 61 million according to the U.S. Census Bureau, and this cohort generates disproportionate demand for diabetes, cardiac, and anticoagulation monitoring. Medicare reimbursement for remote physiologic monitoring, codified in CPT codes 99453 through 99458, has encouraged primary care practices to purchase bedside devices that feed electronic health records directly, and many practices have expanded device inventories since 2020.
Regulatory and funding shifts supply the second and third drivers. FDA's CLIA waiver pathway has produced dozens of waived tests in recent years, including influenza and COVID-19 antigen assays cleared under standard authorizations. The Rural Health Transformation Program, funded at USD 50 billion over fiscal years 2026 to 2030, directs states to equip underserved facilities with diagnostic equipment, creating a government-backed procurement channel for bedside platforms.
Market Restraints and Entry Barriers in U.S. Point-of-Care Technology
Reimbursement compression is the most immediate barrier. The Protecting Access to Medicare Act formula that governs Clinical Laboratory Fee Schedule rates has been delayed repeatedly, leaving CMS to adjust payment for waived tests on a rolling basis. New entrants must price against incumbents whose installed device bases generate recurring cartridge revenue, while Medicare payment for many low-complexity assays now falls below the combined cost of device and consumable.
Certification and integration form the second barrier. Each testing site requires a CLIA certificate from CMS, with a Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation determined by test complexity. New York adds a separate State Department of Health approval regime, and connecting devices to Epic and Oracle Health record systems requires HL7 interface validation that often extends hospital procurement cycles by six to twelve months.
Market Opportunities in U.S. Point-of-Care Technology
Pharmacy-based testing is the nearest large opening. CVS Pharmacy and Walgreens operate thousands of in-store testing points, and the addressable pharmacy pool for respiratory and sexually transmitted infection assays is estimated at USD 1.2 billion annually. Companies with CLIA-waived multiplex panels suited to pharmacist-administered protocols, particularly in states that authorize pharmacists to test and treat, can capture this channel within eighteen months of launch.
Sepsis and cardiac biomarker testing in emergency departments represents a second opening. The CDC estimates that 1.7 million American adults develop sepsis each year, and rapid pathogen identification at the bedside shortens time to appropriate antibiotics. Troponin and procalcitonin point-of-care assays addressing this gap represent an estimated USD 900 million addressable pool, with Texas and Florida emergency departments offering the highest patient throughput for early adoption.
Market at a Glance
| Metric | Value |
|---|---|
| Market Size 2024 | USD 17.8 billion |
| Market Size 2032 | USD 30.6 billion |
| Growth Rate (CAGR) | 7.0% |
| Most Critical Decision Factor | Durability of Medicare Clinical Laboratory Fee Schedule reimbursement rates |
| Largest Region | South region, led by Texas, Florida, and Georgia |
| Competitive Structure | Concentrated among diversified diagnostics majors, with fragmented niche device entrants |
Leading Market Participants
- Abbott
- Danaher (Cepheid)
- Roche Diagnostics
- QuidelOrtho
- Siemens Healthineers
- bioMérieux
- Becton, Dickinson and Company
- Thermo Fisher Scientific
- Sysmex
- Nova Biomedical
Regulatory and Policy Environment for U.S. Point-of-Care Technology
The FDA oversees device entry under the Federal Food, Drug, and Cosmetic Act, with in vitro diagnostic submissions filed through 510(k), De Novo, or PMA pathways and labeling governed by 21 CFR Part 809. CLIA waiver applications are reviewed within FDA's device center, while CMS administers the Clinical Laboratory Improvement Amendments of 1988 certificate system. The amended Quality Management System Regulation under 21 CFR Part 820 takes effect February 2, 2026, aligning device quality systems with ISO 13485 and adding audit requirements for manufacturers.
Reimbursement sits under the Medicare Clinical Laboratory Fee Schedule set by CMS, and PAMA reporting obligations continue to shape rates for waived and moderate-complexity tests. A federal court vacated FDA's laboratory-developed test rule in March 2025, preserving the existing oversight structure for hospital and reference laboratories. Section 524B of the FD&C Act requires premarket cybersecurity documentation for connected devices, adding roughly three to six months to submission timelines.
Long-Term Outlook for U.S. Point-of-Care Technology
By 2032 the U.S. market is projected to reach USD 30.6 billion, with molecular and multiplex platforms growing faster than glucose and coagulation categories. Pharmacy and home-adjacent settings will capture a larger share of respiratory and sexually transmitted infection volume, while hospital emergency departments remain the highest-value setting per test. Connected devices feeding Epic and Oracle Health records will become standard procurement criteria across most institutional buyers.
Consolidation will continue as diversified diagnostics firms acquire niche cartridge makers, and CLIA-waived molecular assays will become standard in physician offices. Reimbursement reform, particularly any replacement of the PAMA formula, would reset pricing across the entire channel and reward manufacturers with low-cost, high-throughput cartridges. Manufacturers that secure waivers and integrate with major EHR vendors will hold the strongest positions through the forecast period.
Frequently Asked Questions
Market Segmentation
- Glucose Monitoring Systems
- Infectious Disease Testing
- Cardiac Markers
- Coagulation Testing
- Blood Gas and Electrolyte Analyzers
- Hospitals and Emergency Departments
- Physician Offices
- Retail Pharmacies
- Home Healthcare
- Urgent Care Centers
- Molecular Diagnostics
- Immunoassay
- Biosensors
- Lateral Flow Immunochromatography
- Hematology
Table of Contents
Research Framework and Methodological Approach
Information
Procurement
Information
Analysis
Market Formulation
& Validation
Overview of Our Research Process
MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.
1. Data Acquisition Strategy
Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.
- Company annual reports & SEC filings
- Industry association publications
- Technical journals & white papers
- Government databases (World Bank, OECD)
- Paid commercial databases
- KOL Interviews (CEOs, Marketing Heads)
- Surveys with industry participants
- Distributor & supplier discussions
- End-user feedback loops
- Questionnaires for gap analysis
Analytical Modeling and Insight Development
After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.
2. Market Estimation Techniques
MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.
Bottom-up Approach
Aggregating granular demand data from country level to derive global figures.
Top-down Approach
Breaking down the parent industry market to identify the target serviceable market.
Supply Chain Anchored Forecasting
MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.
Supply-Side Evaluation
Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.
3. Market Engineering & Validation
Market engineering involves the triangulation of data from multiple sources to minimize errors.
Extensive gathering of raw data.
Statistical regression & trend analysis.
Cross-verification with experts.
Publication of market study.
Client-Centric Research Delivery
MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.